150 related articles for article (PubMed ID: 15188224)
1. [1, 2-Bis(2, 6-difluoro-3-hydroxyphenyl)ethylene-diamine]platinum(II) complexes, compounds for the endocrine therapy of breast cancer - mode of action II: contribution of drug inactivation, cellular drug uptake and sterical factors in the drug-target interaction to the antitumor activity.
Schertl S; Hartmann RW; Batzl-Hartmann C; Bernhardt G; Spruss T; Beckenlehner K; Koch M; Krauser R; Schlemmer R; Gust R; Schönenberger H
Arch Pharm (Weinheim); 2004 Jun; 337(6):349-59. PubMed ID: 15188224
[TBL] [Abstract][Full Text] [Related]
2. [1, 2-Bis(2, 6-difluoro-3-hydroxyphenyl)ethylene-diamine]platinum(II) complexes, compounds for the endocrine therapy of breast cancer - mode of action I: antitumor activity due to the reduction of the endogenous estrogen level.
Schertl S; Hartmann RW; Batzl-Hartmann C; Bernhardt G; Spruss T; Beckenlehner K; Koch M; Krauser R; Schlemmer R; Gust R; Schönenberger H
Arch Pharm (Weinheim); 2004 Jun; 337(6):335-48. PubMed ID: 15188223
[TBL] [Abstract][Full Text] [Related]
3. Platinum(II) complexes interfering with testicular steroid biosynthesis: drugs for the therapy of advanced or recurrent prostate cancers? Preclinical studies.
Schertl S; Hartmann RW; Batzl-Hartmann C; Spruss T; Maucher A; von Angerer E; Schiller CD; Schneider MR; Gust R; Schönenberger H
J Cancer Res Clin Oncol; 2007 Mar; 133(3):153-67. PubMed ID: 17024493
[TBL] [Abstract][Full Text] [Related]
4. [N-ethyl- and [N,N'-diethyl-1,2-bis(2,6-difluoro-3-hydroxyphenyl)-ethylenediamine]dichloroplatinum(II): structure and cytotoxic/estrogenic activity in breast cancer cells.
Gust R; Niebler K; Schönenberger H
J Med Chem; 2005 Nov; 48(23):7132-44. PubMed ID: 16279771
[TBL] [Abstract][Full Text] [Related]
5. [meso-1,2-bis(2,6-dichloro-4-hydroxyphenyl) ethylenediamine]dichloroplatinum(II), a compound with a specific activity on hormone-sensitive breast cancers--evidence for a diethylstilbestrol-like mode of action.
Schlemmer R; Spruss T; Bernhardt G; Schönenberger H
Arch Pharm (Weinheim); 1999 Feb; 332(2):59-69. PubMed ID: 10191716
[TBL] [Abstract][Full Text] [Related]
6. Mono- and polynuclear [alkylamine]platinum(II) complexes of [1,2-bis(4-fluorophenyl)ethylenediamine]platinum(II): synthesis and investigations on cytotoxicity, cellular distribution, and DNA and protein binding.
Kapp T; Dullin A; Gust R
J Med Chem; 2006 Feb; 49(3):1182-90. PubMed ID: 16451082
[TBL] [Abstract][Full Text] [Related]
7. Platinum complexes with a selective action on estrogen receptor-positive mammary tumors.
von Angerer E; Birnböck H; Knebel N
Anticancer Drug Des; 1989 Jun; 4(1):21-35. PubMed ID: 2757751
[TBL] [Abstract][Full Text] [Related]
8. [Aqua-1-(2,6-dichloro-4-hydroxyphenyl)-2-phenylethylenediamine] sulfatoplatinum(II) complexes with variable substituents in the 2-phenyl ring. 3. Investigation of breast cancer inhibiting properties.
Gust R; Faderl M; Schönenberger H
J Cancer Res Clin Oncol; 2000 Nov; 126(11):647-54. PubMed ID: 11079729
[TBL] [Abstract][Full Text] [Related]
9. Antitumor activity of a new platinum(II) complex with low nephrotoxicity and genotoxicity.
Marzano C; Bettio F; Baccichetti F; Trevisan A; Giovagnini L; Fregona D
Chem Biol Interact; 2004 Jun; 148(1-2):37-48. PubMed ID: 15223355
[TBL] [Abstract][Full Text] [Related]
10. 1-(2,6-dichloro-4-hydroxyphenyl)-2-phenylethanes--new biological response modifiers for the therapy of breast cancer. Synthesis and evaluation of estrogenic/antiestrogenic properties.
Schertl S; Hartmann RW; Batzl-Hartmann C; Schlemmer R; Spruss T; Bernhardt G; Gust R; Schönenberger H
Arch Pharm (Weinheim); 2001 Apr; 334(4):125-37. PubMed ID: 11382148
[TBL] [Abstract][Full Text] [Related]
11. Does [meso-1,2-bis(2,6-dichloro-4-hydroxyphenyl)ethylenediamine]- dichloroplatinum(II) act on the hormone-sensitive, murine breast cancer as a biological response modifier? Part 1: The MXT-M-3.2 breast cancer stimulates the growth of an identical second graft; [meso-1,2-bis(2,6-dichloro-4-hydroxyphenyl)ethylenediamine]dichloroplat inum (II) inhibits this process.
Schlemmer R; Spruss T; Bernhardt G; Schönenberger H
Arch Pharm (Weinheim); 2000 Mar; 333(2-3):69-71. PubMed ID: 10783521
[TBL] [Abstract][Full Text] [Related]
12. Cytotoxicity, DNA strand breakage and DNA-protein crosslinking by a novel transplatinum compound in human A2780 ovarian and MCF-7 breast carcinoma cells.
Farrell N; Povirk LF; Dange Y; DeMasters G; Gupta MS; Kohlhagen G; Khan QA; Pommier Y; Gewirtz DA
Biochem Pharmacol; 2004 Sep; 68(5):857-66. PubMed ID: 15294448
[TBL] [Abstract][Full Text] [Related]
13. Improved synthesis of unique estradiol-linked platinum(II) complexes showing potent cytocidal activity and affinity for the estrogen receptor alpha and beta.
Descôteaux C; Leblanc V; Bélanger G; Parent S; Asselin E; Bérubé G
Steroids; 2008 Oct; 73(11):1077-89. PubMed ID: 18572212
[TBL] [Abstract][Full Text] [Related]
14. Studies of the mechanism of action of platinum(II) complexes with potent cytotoxicity in human cancer cells.
Krause-Heuer AM; Grünert R; Kühne S; Buczkowska M; Wheate NJ; Le Pevelen DD; Boag LR; Fisher DM; Kasparkova J; Malina J; Bednarski PJ; Brabec V; Aldrich-Wright JR
J Med Chem; 2009 Sep; 52(17):5474-84. PubMed ID: 19658404
[TBL] [Abstract][Full Text] [Related]
15. Platinum(II) complexes with l-methionylglycine and l-methionyl-l-leucine ligands: synthesis, characterization and in vitro antitumoral activity.
Kaluderović GN; Schmidt H; Paschke R; Kalinowski B; Dietrich A; Mueller T; Steinborn D
J Inorg Biochem; 2007 Mar; 101(3):543-9. PubMed ID: 17223197
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and characterization of platinum(II) oxadiazoline complexes and their in vitro antitumor activity in platinum-sensitive and -resistant cancer cell lines.
Coley HM; Sarju J; Wagner G
J Med Chem; 2008 Jan; 51(1):135-41. PubMed ID: 18072719
[TBL] [Abstract][Full Text] [Related]
17. Steroid hormone receptors as targets for the therapy of breast and prostate cancer--recent advances, mechanisms of resistance, and new approaches.
Hoffmann J; Sommer A
J Steroid Biochem Mol Biol; 2005 Feb; 93(2-5):191-200. PubMed ID: 15860262
[TBL] [Abstract][Full Text] [Related]
18. Does [meso-1,2-bis(2,6-dichloro-4-hydroxyphenyl)ethylenediamine] dichloroplatinum(II) act as an immune response modifier? IV. Inhibition of the proliferation-increasing effect of progressively growing MXT-M-3,2 breast cancer on phagocytes by the title compound.
Schlemmer R; Spruss T; Bernhardt G; Schönenberger H
Arch Pharm (Weinheim); 2001 Oct; 334(10):309-17. PubMed ID: 11759169
[TBL] [Abstract][Full Text] [Related]
19. Enantiomerically pure [1, 2-diamino-1-(4-fluorophenyl)butane]platinum(II) complexes: synthesis and antitumor activity against MCF-7 and MDA-MB 231 breast cancer and LnCaP/FGC prostate cancer cell lines.
Dullin A; Dufrasne F; Gelbcke M; Gust R
Arch Pharm (Weinheim); 2004 Dec; 337(12):654-67. PubMed ID: 15597399
[TBL] [Abstract][Full Text] [Related]
20. Development of cobalt(3,4-diarylsalen) complexes as tumor therapeutics.
Gust R; Ott I; Posselt D; Sommer K
J Med Chem; 2004 Nov; 47(24):5837-46. PubMed ID: 15537341
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
